Form 4: Bristol-Myers Squibb EVP Lenkowsky Reports Equity Transactions

Bristol-Myers Squibb's EVP, Chief Commercial Officer Adam Lenkowsky, reported the vesting of equity awards, tax-related dispositions, and new grants of market share units and performance shares.

Summary

• Adam Lenkowsky, EVP, Chief Commercial Officer, reported multiple equity transactions on March 10, 2026.
• Transactions included the vesting of 1,828 market share units granted in 2022 and 2,000 market share units granted in 2023.
• He also received distributions of 12,002 and 8,241 performance shares earned under the 2023-2025 Long-Term Performance Award.
• Shares were disposed of for tax payments, totaling 831, 913, 3,125, and 2,146 shares, all at a price of $60.13 per share.
• Downward adjustments to shares acquired upon vesting occurred due to performance factors, totaling 205, 216, 5,893, and 4,046 shares.
• Following these transactions, Lenkowsky directly owns 19,135 shares and indirectly owns 5,849.47 shares through the BMS Savings and Investment Program and 2,929 shares by his spouse.
• New grants of 32,653 market share units and 48,980 performance shares were made on March 10, 2026, both cliff vesting on March 10, 2029, subject to performance certification.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting routine executive compensation activities including significant new long-term incentive grants, which align management's interests with future company performance.

Positives

• Significant vesting of previously granted market share units and performance shares, indicating successful achievement of past performance targets.
• New grants of 32,653 market share units and 48,980 performance shares align executive incentives with long-term shareholder value creation.
• The performance share units convert 1:1 into common stock, providing a clear value proposition.

Negatives

• A portion of shares acquired upon vesting was subject to downward adjustment due to performance factors.
• A substantial number of shares were withheld for tax payments, reducing the net shares received by the executive.

Future Outlook

The new grants of market share units and performance shares, vesting in 2029, indicate a long-term incentive structure for the executive, aligning future performance with shareholder returns through specific payout factors tied to stock price performance and relative total shareholder return.

Industry Context

StockSavvy.ai notes that the use of market share units and performance shares with performance-based payout factors is a common practice in the pharmaceutical industry to incentivize executive performance and align it with long-term company growth and shareholder value, especially given the long development cycles and regulatory hurdles inherent in the sector.

Comparison to Industry Standards

• StockSavvy.ai observes that Bristol-Myers Squibb's executive compensation structure, utilizing market share units and performance shares with performance-based payout factors (e.g., Total Return and rTSR Floor), is consistent with best practices seen in major pharmaceutical companies like Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK).
• These structures aim to link executive pay directly to company performance relative to peers and overall shareholder returns, ensuring competitive and performance-driven compensation.

Stakeholder Impact

• Shareholders: The vesting and new grants align executive incentives with shareholder interests, potentially leading to long-term value creation. Tax withholdings and performance adjustments are standard.
• Management: Adam Lenkowsky's compensation package is detailed, reflecting his ongoing role and incentives.

Next Steps

• The newly granted market share units and performance shares are scheduled to cliff vest on March 10, 2029, subject to certification of performance results by the Board.

Key Dates

Recommendation

This Form 4 details routine executive compensation activities, including the vesting of prior equity awards and the grant of new long-term incentives. While the new grants are substantial and align executive interests with future performance, these are expected events and do not provide new fundamental information that would warrant a change in investment recommendation. The transactions reflect standard compensation practices rather than a strategic shift or unexpected financial performance.

Keywords

Bristol-Myers Squibb, BMY, Adam Lenkowsky, SEC Form 4, Insider Trading, Equity Awards, Market Share Units, Performance Shares, Executive Compensation, Stock Vesting, Tax Withholding